AbbVie Inc. ABBV
264.34
(0.78)
(0.29%)
as of 25 Sep
- Market cap
- $467.4B
- P/E
- 74.7×
Follow ABBV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
AbbVie Inc. (ABBV) Current ratio
AbbVie Inc.'s current ratio at the end of the quarter to 30 June 2026 was 0.8×, up 0.1× from fiscal 2025 (0.7×). Over the past ten years it has ranged from 0.7× (fiscal 2024) to 3.2× (fiscal 2019); the current reading is higher than 18% of that period. That is below the Drug Manufacturers General industry median of 1.3× and below the Healthcare sector median of 3.0×.
Current ratio, annual
Annual
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 0.7× | 1.68% |
| FY2024 | 0.7× | (24.30%) |
| FY2023 | 0.9× | (9.50%) |
| FY2022 | 1.0× | 21.44% |
| FY2021 | 0.8× | (5.92%) |
| FY2020 | 0.8× | (73.46%) |
| FY2019 | 3.2× | 223.27% |
| FY2018 | 1.0× | (22.93%) |
| FY2017 | 1.3× | (22.94%) |
| FY2016 | 1.7× | 10.51% |
Quarterly
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 0.8× | 1.52% |
| Mar 2026 | 0.8× | 18.64% |
| Dec 2025 | 0.7× | (7.34%) |
| Sep 2025 | 0.7× | (1.54%) |
| 42 more quarters | Free account |
Against its own ten years
Low 0.7×
High 3.2×
Ten-year median
1.0×
Current reading's percentile
18
Current ratio against peers
| Company | Current ratio |
|---|---|
| AMGN Amgen Inc. compare | 1.4× |
| LLY Eli Lilly and Company compare | 1.4× |
| MRK Merck & Co., Inc. compare | 1.3× |
| PFE Pfizer Inc. compare | 1.3× |
| GILD Gilead Sciences, Inc. compare | 1.3× |
| JNJ Johnson & Johnson compare | 1.1× |
| AZN AstraZeneca PLC compare | 0.9× |
| NVS Novartis AG compare | 0.9× |
| ABBV AbbVie Inc. | 0.8× |
| Drug Manufacturers General industry median | 1.3× |
| Healthcare sector median | 3.0× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ABBV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement